Contrasting BeOne Medicines (NASDAQ:ONC) & Korro Bio (NASDAQ:KRRO)

BeOne Medicines (NASDAQ:ONC) and Korro Bio (NASDAQ:KRRO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares BeOne Medicines and Korro Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34 billion	6.61	$286.93 million	$4.47	72.05
Korro Bio	$3.84 million	39.23	-$117.26 million	($11.67)	-0.90

BeOne Medicines has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3, meaning that its stock price is 200% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for BeOne Medicines and Korro Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1	2	11	2	2.88
Korro Bio	1	2	6	3	2.92

BeOne Medicines presently has a consensus price target of $394.00, indicating a potential upside of 22.33%. Korro Bio has a consensus price target of $16.71, indicating a potential upside of 59.95%. Given Korro Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Korro Bio is more favorable than BeOne Medicines.

Institutional & Insider Ownership

48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BeOne Medicines and Korro Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Summary

BeOne Medicines beats Korro Bio on 10 of the 15 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.